Literature DB >> 20457695

Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

Brian R Miller1, Stephen J Demarest, Alexey Lugovskoy, Flora Huang, Xiufeng Wu, William B Snyder, Lisa J Croner, Norman Wang, Aldo Amatucci, Jennifer S Michaelson, Scott M Glaser.   

Abstract

Single-chain Fvs (scFvs) are commonly used building blocks for creating engineered diagnostic and therapeutic antibody molecules. Bispecific antibodies (BsAbs) hold particular interest due to their ability to simultaneously bind and engage two distinct targets. We describe a technology for producing stable, scalable IgG-like bispecific and multivalent antibodies based on methods for rapidly engineering thermally stable scFvs. Focused libraries of mutant scFvs were designed using a combination of sequence-based statistical analyses and structure-, and knowledge-based methods. Libraries encoding these designs were expressed in E. coli and culture supernatants-containing soluble scFvs screened in a high-throughput assay incorporating a thermal challenge prior to an antigen-binding assay. Thermally stable scFvs were identified that retain full antigen-binding affinity. Single mutations were found that increased the measured T(m) of either the V(H) or V(L) domain by as much as 14 degrees C relative to the wild-type scFv. Combinations of mutations further increased the T(m) by as much as an additional 12 degrees C. Introduction of a stability-engineered scFv as part of an IgG-like BsAb enabled scalable production and purification of BsAb with favorable biophysical properties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457695     DOI: 10.1093/protein/gzq028

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  60 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

3.  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Authors:  David H Aggen; Adam S Chervin; Francis K Insaidoo; Kurt H Piepenbrink; Brian M Baker; David M Kranz
Journal:  Protein Eng Des Sel       Date:  2010-12-14       Impact factor: 1.650

4.  Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

Authors:  Mark C Julian; Christine C Lee; Kathryn E Tiller; Lilia A Rabia; Evan K Day; Arthur J Schick; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2015-09-19       Impact factor: 1.650

Review 5.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 6.  Protein stability by number: high-throughput and statistical approaches to one of protein science's most difficult problems.

Authors:  Thomas J Magliery; Jason J Lavinder; Brandon J Sullivan
Journal:  Curr Opin Chem Biol       Date:  2011-04-15       Impact factor: 8.822

7.  Mutations in Antibody Fragments Modulate Allosteric Response Via Hydrogen-Bond Network Fluctuations.

Authors:  Amit Srivastava; Malgorzata B Tracka; Shahid Uddin; Jose Casas-Finet; Dennis R Livesay; Donald J Jacobs
Journal:  Biophys J       Date:  2016-05-10       Impact factor: 4.033

Review 8.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

9.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.